Visible Genomics

Visible Genomics is a private health-tech and diagnostics company focused on genetic risk assessment for age-related macular degeneration (AMD). The company markets commercial cheek-swab-based tests that combine genetic information with demographic, behavioral, ocular, and other health factors to estimate lifetime AMD risk or risk of progression to advanced disease. Its principal offering is the AMDiGuard product line, which includes separate risk and progression assessments for different patient populations. Visible Genomics sells through both direct-to-consumer and eye-care-provider channels and positions its products as tools for personalized monitoring, prevention, and clinical management of vision loss risk.